Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

BB, I'm not in disagreement and my hope

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SocialBoom Member Profile
 
Followed By 15
Posts 2,203
Boards Moderated 0
Alias Born 01/31/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:02:53 PM
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting GlobeNewswire Inc. - 5/16/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2019 6:50:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 6:49:35 AM
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 5/1/2019 5:00:00 AM
New Drug Submission Filed for Vascepa® with Health Canada GlobeNewswire Inc. - 4/29/2019 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:14 AM
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 GlobeNewswire Inc. - 4/24/2019 6:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/15/2019 5:08:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 5:09:07 PM
Vascepa® Granted Priority Review Status from Health Canada GlobeNewswire Inc. - 3/29/2019 5:45:15 PM
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) t... GlobeNewswire Inc. - 3/28/2019 4:51:57 PM
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from t... GlobeNewswire Inc. - 3/28/2019 5:00:00 AM
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68... GlobeNewswire Inc. - 3/19/2019 6:00:00 AM
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Lev... GlobeNewswire Inc. - 3/18/2019 4:15:00 PM
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™ PR Newswire (US) - 3/18/2019 9:00:00 AM
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Athero... GlobeNewswire Inc. - 3/16/2019 5:30:00 PM
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activi... GlobeNewswire Inc. - 3/6/2019 8:25:00 AM
Amarin to Present at Cowen’s 39th Annual Health Care Conference GlobeNewswire Inc. - 3/5/2019 6:00:00 AM
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Is... GlobeNewswire Inc. - 3/4/2019 4:30:00 PM
Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights Business Wire - 3/1/2019 5:00:00 PM
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & En... Business Wire - 2/27/2019 2:25:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 6:39:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 6:31:09 AM
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 2/27/2019 5:00:00 AM
SocialBoom   Tuesday, 02/12/19 09:17:05 AM
Re: Biobillionair post# 175773
Post # of 193539 
BB, I'm not in disagreement and my hope is we GIA.

My point is GILD is an absolute dumpster fire. I'm talking a raging white hot dumpster fire.

GILD is losing ground to Enata and AbbVie in Hep C, and if Glaxo and Merk keep making progress on their HIV platforms that is a massive revenue risk to GILD not even considering yesterday's NASH fail and Renaxa going generic soon.

Their management is in disarray and they are getting downgrades and can't figure out which way to turn and have resulted to doing stock buybacks when in the best case they see their revenues shrinking 15% YOY.

It's a wounded animal....

They will be looking for very de/risked plays and will be ready to unload cash to start to turn this around. They have no choice.

It's in that light, I'm saying keep it on the radar. Makes way more sense to me than PFE, but who knows?


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist